Hikal fills key division vacancy and closes internal probe
Ravi Khadabadi takes over the Crop Protection & Specialty Chemicals unit, while an investigation into employee irregularities concludes with no financial impact.
— 4 earlier stories on Hikal Ltd. →What's new
- Ravi Khadabadi is the new President of the Crop Protection & Specialty Chemicals division.
- The appointment fills a vacancy left by the previous head's superannuation in April.
- An external review of December 2025 irregularities found only preponed sales, now corrected.
Why this matters
The appointment provides leadership continuity for a core revenue-generating segment. Closing the investigation into employee conduct removes a governance overhang that had lingered since late 2025.
What we're watching
- How Khadabadi integrates into the leadership team.
- Whether the internal controls implemented prevent further sales-timing issues.
- Performance of the Crop Protection division in the upcoming quarterly results.
The full read
Hikal has moved to stabilize its leadership and clear its governance record. On May 27, 2026, the board approved the appointment of Ravi Khadabadi as President of the Crop Protection & Specialty Chemicals division. This unit accounts for a large portion of the company's revenue, making the appointment a necessary step to restore continuity after the previous head retired in April. Simultaneously, the company provided a final update on employee irregularities first flagged in December 2025. An external review determined the issue was limited to the preponement of genuine sales. Hikal corrected these figures within the quarter and relieved the employees involved. Management claims there is no material impact on current or prior period financials. By resolving the investigation and filling a key executive seat, Hikal removes two sources of uncertainty that have weighed on the company's management narrative.
Questions answered
- Who is the new head of the Crop Protection & Specialty Chemicals division?
- Ravi Khadabadi has been appointed as President of the division. He holds master's degrees in chemistry and polymers and has prior experience in pharma and specialty chemicals.
- What was the outcome of the investigation into employee irregularities?
- The external review found that employees had preponed genuine sales. The company corrected these entries within the same quarter and has since relieved the involved employees.
- Did the irregularities impact Hikal's financial statements?
- No. Management concluded that there is no impact on current or prior period financials.
- Why was this leadership position vacant?
- The vacancy arose following the superannuation of the previous division head in April 2026.
Hikal Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on HIKAL →- 27 May 2026 · 4:16 PM IST Hikal fills key division vacancy and closes internal probe
- 38d ago Hikal's Q4 profit sinks under ₹47 cr write-down; no FY27 guidance
- 45d ago Hikal's earnings release adds no new data to prior disclosures.
- 45d ago Hikal's latest investor presentation adds no new information
- 45d ago Hikal swings to a loss as USFDA issues and impairments bite